Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05268991 · ClinicalTrials.gov registry record
Aging and Frailty Study
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 25
- Enrollment target
NCT05268991: Completed study, sponsored by Wake Forest University Health Sciences.
NCT05268991 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05268991 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
The purpose of this research study is to compare methods to help personalize the prediction of chemotherapy side effects for older adults and to evaluate whether chemotherapy causes changes in the body that are associated with aging.
Primary Outcome
The SPPB will be used to assess lower extremity physical function (a short walk of 4 meters, timed repeated chair stands and balances tests). Each task is scored ranging from 0-4 (0 = unable to complete; 4 = highest performance level) with the total sum score range from 0-12. Lower scores indicate increased risk of disability, hospitalization and worse survival among older adults with and without cancer.
Interventions
- OTHER Geriatric Assessments and Frailty Indices
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-05-02 |
| Est. Completion | 2025-06-13 |
What the finished NCT05268991 record still lists
NCT05268991 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Geriatric Assessments and Frailty Indices is the first listed.
NCT05268991 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05268991 about?
NCT05268991 is a clinical study titled "Aging and Frailty Study". The purpose of this research study is to compare methods to help personalize the prediction of chemotherapy side effects for older adults and to evaluate whether chemotherapy causes changes in the body that are associated with aging.
What is the current status of trial NCT05268991?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2022-05-02. Estimated completion is 2025-06-13.
What interventions are being tested in trial NCT05268991?
The interventions under investigation include: Geriatric Assessments and Frailty Indices (OTHER).
Who is sponsoring clinical trial NCT05268991?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI